Akari Virtual Investor “What This Means” Discussing its Expanded ADC Pipeline - Feb. 11, 2026
As part of the segment, Mr. Gaslightwala discussed Akari’s recently announced patent filing and the introduction of AKTX-102, the Company’s second ADC pipeline candidate targeting CEACAM5-expressing solid tumors. The discussion highlighted how this milestone underscores the scalability of Akari’s PH1-powered ADC platform and its ability to generate multiple differentiated therapeutic programs.
▶︎
AKTX on Virtual Investor "What This Means" Highlighting its Granted India Patent: June 25, 2025
▶︎
Akari on Virtual Investor “What This Means” - December 18, 2025
▶︎
Princess Of Boogie Woogie Delights Everyone
▶︎
NEVER Buy These 5 Types of Homes (I'm a Lawyer)
▶︎
This Hated Corner of the Stock Market Is Yielding Big Returns | Merryn Talks Money
▶︎
Why Aliens Would NEVER Invade Africa
▶︎
Learn From Proficiency: Here’s How Today’s Market Wizards Made Their Fortunes | Investing With IBD
▶︎
Akari in Virtual Investor “What This Means” Discussing Partnership with WuXi XDC - April 9, 2026
▶︎
Stop Walking 10,000 Steps/Day (do this for 10 minutes instead)
▶︎
Akari CEO Corner Highlighting its Strategic Progress and Path to the Clinical - March 13, 2026
▶︎
Nobody Breaks Celebrities Like Rowan Atkinson
▶︎
When an audition changed TV forever
▶︎
The FULL VIDEO of Trump they didn’t want released
▶︎
The UNTHINKABLE is About to Happen to SpaceX Stock
▶︎
Akari CEO Corner: 2025 Progress and Path to Clinical Transition In 2026 - January 9, 2026
▶︎
Akari Discusses Breakthrough Potential of AKTX-101 and Novel ADC Platform - May 28, 2026
▶︎
You're Doing Push-Ups Wrong... This Is Why You're Not Getting Stronger
▶︎
Conan O’Brien Mocks Trump At Harvard Commencement | Crowd Erupts During Viral Speech
▶︎
Introducing the American AI Sovereign Wealth Fund Act
▶︎